1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Video Interview: C4 Therapeutics Targets Protein Degradation

 
• By Mike Ward

Finding a way to trick the ubiquitin proteasome system, C4 Therapeutics, a spin-out from Harvard's Dana-Farber Cancer Institute, has developed a method to target any disease-causing protein for degradation. Fresh from announcing the creation of the company, a $73m series A financing, and a deal with Roche which has a potential biodollar value north of $750m, C4 Therapeutics co-founder and executive chair Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works.

Finding a way to trick the ubiquitin proteasome system, C4 Therapeutics, a spin-out from Harvard's Dana-Farber Cancer Institute, has developed a method to target any disease-causing protein for degradation. Fresh from announcing the creation of the company, a $73m series A financing, and a deal with Roche which has a potential biodollar value north of $750m, C4 Therapeutics co-founder and executive chair Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works.

This interview took place during EBD Group's Biotech Showcase in San Francisco, Jan. 11-13, 2016. Further panel discussions and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

More from Therapy Areas

Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag

 
• By Alaric DeArment

The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.

Wegovy’s Win In MASH Gives Novo A Much-Needed Edge Over Lilly

 
• By Manas Mishra

Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.

Leo Keeps On Profitable Path With Solid H1 Sales Growth

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.